A detailed history of Susquehanna International Group, LLP transactions in Immunovant, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 195,307 shares of IMVT stock, worth $5.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
195,307
Previous 121,692 60.49%
Holding current value
$5.37 Million
Previous $3.21 Million 67.25%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $2.03 Million - $2.03 Million
73,615 Added 60.49%
195,307 $5.37 Million
Q2 2024

Aug 15, 2024

SELL
$25.1 - $31.61 $3.06 Million - $3.85 Million
-121,951 Reduced 50.05%
121,692 $3.21 Million
Q1 2024

May 07, 2024

BUY
$30.27 - $43.79 $1.36 Million - $1.97 Million
44,931 Added 22.61%
243,643 $7.87 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $2.58 Million - $3.64 Million
82,376 Added 70.81%
198,712 $8.37 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $1.83 Million - $3.94 Million
98,521 Added 553.02%
116,336 $4.47 Million
Q2 2023

Aug 11, 2023

SELL
$14.2 - $23.75 $1.76 Million - $2.95 Million
-124,214 Reduced 87.46%
17,815 $337,000
Q1 2023

May 16, 2023

BUY
$15.27 - $19.72 $1.84 Million - $2.38 Million
120,780 Added 568.4%
142,029 $2.2 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $55,257 - $148,833
8,385 Added 65.18%
21,249 $377,000
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $29,687 - $48,118
-7,554 Reduced 37.0%
12,864 $72,000
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $219,405 - $366,758
-64,913 Reduced 76.07%
20,418 $80,000
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $448,720 - $777,723
-88,680 Reduced 50.96%
85,331 $470,000
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $624,310 - $793,803
-85,172 Reduced 32.86%
174,011 $1.48 Million
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $65,978 - $107,014
9,412 Added 3.77%
259,183 $2.25 Million
Q2 2021

Aug 11, 2021

BUY
$9.4 - $16.85 $1.95 Million - $3.49 Million
207,373 Added 489.11%
249,771 $2.64 Million
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $327,562 - $1.24 Million
25,043 Added 144.3%
42,398 $680,000
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $8,980 - $13,019
-247 Reduced 1.4%
17,355 $802,000
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $397,981 - $684,717
17,602 New
17,602 $619,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.